Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Ulcerative Colitis

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Ulcerative Colitis

9 stories · every one Fact-Checked
Emvistegrast, Gilead’s investigational oral α4β7 integrin inhibitor, being studied for moderately to severely active ulcerative colitisHealth TidingsGilead Reports Positive Results for Emvistegrast in Ulcerative ColitisGilead’s investigational oral α4β7 integrin inhibitor emvistegrast met the Phase 2 SWIFT trial’s primary endpoint in moderately to severely active ulcerative colitis.20 Oct 2026 · 3 min read
Fact-Checked
Spyre Therapeutics SPY003 anti-IL-23 antibody Phase 2 SKYLINE trial for ulcerative colitisClinical TrialsSpyre’s SPY003 Delivers a Strong Phase 2 Signal in Ulcerative ColitisSpyre Therapeutics’ investigational anti-IL-23 antibody SPY003 significantly reduced histologic disease activity in moderately-to-severely active ulcerative colitis in the Phase 2 SKYLINE trial, supporting further development of the antibody…9 Sep 2026 · 3 min read
Fact-Checked
Stelara ustekinumab FDA approval for pediatric ulcerative colitisHealth TidingsFDA Expands Stelara to Pediatric Ulcerative ColitisThe FDA approved Stelara (ustekinumab) for children aged 2 years and older with moderately to severely active ulcerative colitis, extending its use across both major forms of pediatric…29 Aug 2026 · 3 min read
Fact-Checked
Abivax advances obefazimod toward FDA New Drug Application after positive pre-NDA meeting for moderately to severely active ulcerative colitis.Health TidingsAbivax Advances Obefazimod Toward FDA NDA for Ulcerative ColitisAbivax has completed a positive pre-NDA meeting with the U.S. FDA for obefazimod in moderately to severely active ulcerative colitis.31 Jul 2026 · 3 min read
Fact-Checked
Duvakitug anti-TL1A monoclonal antibody Phase 2b clinical trial in moderately to severely active ulcerative colitisHealth TidingsDuvakitug Improves Clinical Remission in Ulcerative Colitis TrialPhase 2b results published in The Lancet Gastroenterology & Hepatology show that duvakitug, an investigational anti-TL1A monoclonal antibody from Teva and Sanofi, significantly increased clinical remission compared with…20 Jul 2026 · 3 min read
Fact-Checked
abivaxClinical TrialsAbivax Reports Positive Phase 3 Maintenance Data for Obefazimod in Refractory Ulcerative ColitisAbivax announced topline results from ABTECT Maintenance Part 2, the supplemental Phase 3 study of obefazimod in ulcerative colitis.30 Jun 2026 · 3 min read
Fact-Checked
Merck belzutifan and lenvatinib combination receives positive EU CHMP opinion for previously treated advanced clear-cell renal cell carcinoma.Clinical TrialsMerck’s Tulisokibart Shows Strong Phase 3 Efficacy in Ulcerative ColitisMerck reported positive Phase 3 results for tulisokibart in moderately to severely active ulcerative colitis.22 Jun 2026 · 4 min read
Fact-Checked
abivaxClinical TrialsAbivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative ColitisAbivax has reported positive Phase 3 maintenance results for obefazimod in ulcerative colitis, with both 25 mg and 50 mg doses achieving significant clinical remission and broad efficacy…3 Jun 2026 · 3 min read
Fact-Checked
aakash-dhage-i8hEC6ea8a8-unsplashClinical TrialsSpyre’s SPY001 Pushes the Boundary of UC Care with Promising Induction ResultsSPY001 met the primary endpoint in the Phase 2 SKYLINE trial, delivering significant histologic improvement along with strong remission and endoscopic response rates in ulcerative colitis patients.15 Apr 2026 · 3 min read
Fact-Checked
Page 1 of 1